Advantage Trust Company’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Advantage Trust Company’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	+3,250	New	+$190K	0.08%	61
2025 Q4	–	Sell	-3,250	Closed	-$156K	–	190
2025 Q3	$156K	Hold	3,250	–	–	0.07%	67
2025 Q2	$132K	Buy	3,250 +3,050	+1,525%	+$123K	0.07%	72
2025 Q1	$8.76K	Hold	200	–	–	0.01%	138
2024 Q4	$8.6K	Hold	200	–	–	0.01%	154
2024 Q3	$8.87K	Sell	200 -3,250	-94%	-$139K	0.01%	144
2024 Q2	$137K	Sell	3,450 -720	-17%	-$29.2K	0.1%	54
2024 Q1	$180K	Hold	4,170	–	–	0.13%	45
2023 Q4	$174K	Buy	+4,170	New	+$158K	0.14%	45

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Advantage Trust Company's XPH Position: Q2 2026 in Review

Advantage Trust Company opened a new position in State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2026: 3,250 shares worth $215K. The stake represents 0.08% of the portfolio and ranks #61 among its holdings. This is a return to the name: Advantage Trust Company previously reported a position in XPH as recently as Q3 2025.

Advantage Trust Company first reported a position in XPH in Q4 2023 and has held it in 9 quarters since. 92 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

Advantage Trust Company held 3,250 shares of State Street SPDR S&P Pharmaceuticals ETF worth $215K as of Q2 2026.
State Street SPDR S&P Pharmaceuticals ETF was a new Advantage Trust Company position in Q2 2026.
State Street SPDR S&P Pharmaceuticals ETF made up 0.08% of Advantage Trust Company's portfolio in Q2 2026, its #61 holding.
Advantage Trust Company first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2023 and has held it in 9 quarters since.
92 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Advantage Trust Company's 13F filing for Q2 2026, filed 17 Jul 2026.